Literature DB >> 2478787

Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.

H Pouleur1, C Hanet, E Schröder, J Col, H Van Mechelen, J Etienne, M F Rousseau.   

Abstract

The purpose of this study was to examine the time course of the changes in left ventricular inotropic state after intravenous pimobendan administration. In conscious dogs, cumulative doses of 1 and 2.5 mg of pimobendan significantly increased heart rate and the isovolumic indices of inotropic state and relaxation. The maximal effect, however, required 2 h to be present. The changes in cardiac index and capillary wedge pressure after the intravenous administration of 5 mg to patients with heart failure confirmed this slightly delayed action of pimobendan. Accordingly, the effects of pimobendan on left ventricular inotropic state in patients with moderate to severe heart failure were determined during cardiac catheterization 130-150 min after injection of 5 (n = 3) or 2.5 (n = 4) mg. After drug administration, heart rate increased slightly (+7 beats/min; NS) while left ventricular end-diastolic and systolic pressure both decreased significantly (from 22.7 to 9.2 mm Hg, p less than 0.007 and from 123 to 90 mm Hg, p less than 0.025, respectively). The isovolumic index of contractility (dP/dt)/DP40 increased by 19.6 +/- 14.7% (p less than 0.02) and the slope of the late systolic stress-volume relationship improved by 48% (p less than 0.05). It is concluded that pimobendan is a positive inotropic agent in the failing human heart as well as a powerful veno- and arteriodilator.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478787

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Pharmacokinetic profile and tolerability of pimobendan in patients with terminal renal insufficiency.

Authors:  M Przechera; W Roth; V Kühlkamp; T Risler; M Haehl
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Calcium sensitising agents in heart failure.

Authors:  L Mathew; S D Katz
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

Review 4.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

5.  Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats.

Authors:  Keisuke Sugimoto; Kazutoshi Sugita; Kensuke Orito; Yoko Fujii
Journal:  Animals (Basel)       Date:  2022-04-11       Impact factor: 3.231

Review 6.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

7.  Effects of pimobendan on left atrial transport function in cats.

Authors:  Samantha L Kochie; Karsten E Schober; Jaylyn Rhinehart; Randolph L Winter; John D Bonagura; Annie Showers; Vedat Yildez
Journal:  J Vet Intern Med       Date:  2020-11-26       Impact factor: 3.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.